Patent application number | Description | Published |
20080261225 | METHOD AND KIT FOR DETECTING A TARGET PROTEIN USING A DNA APTAMER - A method and a kit for detecting a target protein in a sample with a signal amplification strategy are provided. The signal amplification strategy is established for the aptamer-based molecular recognition of a target protein with concomitant release of single-stranded DNA (G-DNA), which binds complementarily to a single-stranded RNA comprising a fluorophore and a quencher (“F-RNA-Q”). The fluorescence-quenched RNA is then degraded by RNase H to result in a fluorescence signal, and the undamaged G-DNA is recycled to yield fluorescence amplification. | 10-23-2008 |
20090029390 | METHOD FOR QUANTITATIVE ANALYSIS OF INTERACTIONS BETWEEN HIF-1ALPHA C-TERMINAL PEPTIDES AND CBP OR p300 PROTEINS AND METHOD OF SCREENING INHIBITORS USING THE SAME - The present invention relates to a method for quantitative analysis of interactions between fluorescein-labeled HIF-1α (alpha) C-terminal peptides and cAMP-responsive element binding protein (CBP) or p300 proteins, and a method of screening inhibitors against the formation of HIF-1α-p300 or HIF-1α-CBP protein complexes using the above method. | 01-29-2009 |
20100184146 | PLASMID FOR EXPRESSING THIOREDOXIN FUSION PROTEIN AND METHOD FOR PRODUCING TARGET PROTEIN USING SAME - The present invention provides a plasmid for expressing a thioredoxin fusion protein comprising thioredoxin as a fusion partner, an | 07-22-2010 |
20110027772 | Antigen Detection Kit and Method - An antigen detection kit and an antigen detection method using the same are provided. The antigen detection kit comprises a capture antibody, a detection antibody bound to a single stranded DNA oligonucleotide, a single stranded RNA oligonucleotide complementary sequence to the DNA oligonucleotide, and an RNase. | 02-03-2011 |
20110076679 | 3'-O-FLUORESCENTLY MODIFIED NUCLEOTIDES AND USES THEREOF - The present invention relates to a DNA sequencing method using a nucleoside triphosphate with a fluorescent blocking group on its 3′-OH end as a reversible terminator. Further, the present invention relates to sequencing-by-synthesis method using the mono-modified reversible terminator (MRT), the novel nucleotide monomer having a reversible fluorescent blocking group removable chemically or enzymatically at its 3′-OH end. The sequencing method of the present invention facilitates sequencing of bases inserted by terminating extension of a nucleotide chain by the nucleotide monomer and then detecting fluorescence signal from 3′-OH end. At this time, after analyzing the fluorescence signal, the blocking group conjugated to the 3′-OH end can be effectively removed, indicating that a free 3′-OH functional group can be successfully restored, so that the next monomer insertion is possible, making continuous sequencing possible. | 03-31-2011 |
Patent application number | Description | Published |
20120064531 | MODIFIED NUCLEOTIDE AND REAL-TIME POLYMERASE REACTION USING THE SAME - The present invention relates to a modified nucleotide and real-time polymerase reaction using the nucleotide. Specifically, the present invention relates to a fluorescence material linked-nucleotide, a composition for real-time polymerase reaction comprising the nucleotide, an analysis kit and an analysis method. In the present invention, the fluorescence material linked-nucleotide serves the dual roles of producing fluorescence signal as well as being used as a substrate. Therefore, the present invention is economically advantageous because it is unnecessary to prepare probes, but can be applied to analyze various real-time polymerase reactions such as PCR, RCA and isothermal polymerization reaction, and shows higher quality of performance than the past methods. | 03-15-2012 |
20140255307 | CONTRAST MEDIUM COMPOSITION AND METHOD OF BIO IMAGINATION USING THE SAME - The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment. | 09-11-2014 |